Does serum bilirubin level on admission predict TIMI flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI

Angiology

Volumn 65, Issue 3, 2014, Pages 198-204

  Celik, Turgay ^a   Kaya, Mehmet G ^b   Akpek, Mahmut ^b   Yarlioglues, Mikail ^b   Sarli, Bahadir ^b   Topsakal, Ramazan ^b   Gibson, Charles Michael ^c  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

bilirubin; no reflow; primary percutaneous coronary intervention; ST segment elevation myocardial infarction

Indexed keywords

BILIRUBIN;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD CLOT LYSIS; CARDIOVASCULAR MORTALITY; CORONARY ARTERY BLOOD FLOW; FEMALE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS;

BILIRUBIN; NO-REFLOW; PRIMARY PERCUTANEOUS CORONARY INTERVENTION; ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION;

BILIRUBIN; CORONARY CIRCULATION; CORONARY DISEASE; DIAGNOSTIC TESTS, ROUTINE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 84893528818     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712474948     Document Type: Article

References (32)

1. Kaya MG, Uyarel H, Akpek M, et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012 ; 109 (4). 486-491
2. Akpek M, Kaya MG, Uyarel H, et al. The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI. Atherosclerosis. 2011 ; 219 (1). 334-341
3. Topsakal R, Kaya MG, Karakaya E, et al. Relationship between no-reflow phenomenon and serotonin levels in patients with acute ST-elevation myocardial infarction who underwent primary percutaneous intervention. Anadolu Kardiyol Derg. 2010 ; 10 (3). 253-259
4. Reffelmann T, Kloner RA. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol. 2006 ; 101 (5). 359-372
5. Sahin O, Akpek M, Elcik D, et al. Bilirubin levels and the burden of coronary atherosclerosis in patients with STEMI. Angiology. 2013 ; 64 (3). 200-204
6. Breimer LH, Mikhailidis DP. Could carbon monoxide and bilirubin be friends as well as foes of the body?. Scand J Clin Lab Invest. 2010 ; 70 (1). 1-5
7. Okuhara K, Kisaka T, Ozono R, et al. Change in bilirubin level following acute myocardial infarction is an index for heme oxygenase activation. South Med J. 2010 ; 103 (9). 876-881
8. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985 ; 312 (14). 932-936
9. Akpek M, Elcik D, Kalay N, et al. The prognostic value of serum gamma glutamyl transferase activity on admission in patients with STEMI undergoing primary PCI. Angiology. 2012 ; 63 (8). 579-585
10. Kaya MG, Yalcin R, Okyay K, et al. Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction. Tex Heart Inst J. 2012 ; 39 (4). 500-506
11. Akpek M, Kaya MG, Lam YY, et al. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with st-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012 ; 110 (5). 621-627
12. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993 ; 329 (22). 1615-1622
13. Kaya MG, Arslan F, Abaci A, van der Heijden G, Timurkaynak T, Cengel A. Myocardial blush grade: a predictor for major adverse cardiac events after primary PTCA with stent implantation for acute myocardial infarction. Acta Cardiol. 2007 ; 62 (5). 445-451
14. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996 ; 93 (2). 223-228
15. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002 ; 105 (5). 656-662
16. Huczek Z, Kochman J, Filipiak KJ, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2005 ; 46 (2). 284-290
17. Serdar Z, Serdar A, Altin A, Eryilmaz U, Albayrak S. The relation between oxidant and antioxidant parameters and severity of acute coronary syndromes. Acta Cardiol. 2007 ; 62 (4). 373-380
18. Amanvermez R, Acar E, Gunay M, BaydIn A, Yardan T, Bek Y. Hsp 70, hsCRP and oxidative stress in patients with acute coronary syndromes. Bosn J Basic Med Sci. 2012 ; 12 (2). 102-107
19. Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem. 1994 ; 269 (24). 16712-16719
20. Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem. 2000 ; 46 (11). 1723-1727
21. Nakayama M, Takahashi K, Komaru T, et al. Increased expression of heme oxygenase-1 and bilirubin accumulation in foam cells of rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2001 ; 21 (8). 1373-1377
22. Stocker R. Antioxidant activities of bile pigments. Antioxid Redox Signal. 2004 ; 6 (5). 841-849
23. Rigato I, Ostrow JD, Tiribelli C. Bilirubin and the risk of common non-hepatic diseases. Trends Mol Med. 2005 ; 11 (6). 277-283
24. Wu TW, Wu J, Li RK, Mickle D, Carey D. Albumin-bound bilirubins protect human ventricular myocytes against oxyradical damage. Biochem Cell Biol. 1991 ; 69 (10-11). 683-688
25. Yano Y, Ozono R, Oishi Y, et al. Genetic ablation of the transcription repressor Bach1 leads to myocardial protection against ischemia/reperfusion in mice. Genes Cells. 2006 ; 11 (7). 791-803
26. Melo LG, Agrawal R, Zhang L, et al. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation. 2002 ; 105 (5). 602-607
27. Yet SF, Tian R, Layne MD, et al. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res. 2001 ; 89 (2). 168-173
28. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003 ; 108 (16). 1912-1916
29. Minuz P, Fava C, Lechi A. Lipid peroxidation, isoprostanes and vascular damage. Pharmacol Rep. 2006 ; 58 (suppl). 57-68
30. Marcantoni E, Di Francesco L, Dovizio M, Bruno A, Patrignani P. Novel insights into the vasoprotective role of heme oxygenase-1[published online February 22, 2012]. Int J Hypertens. 2012 ; 2012: 127910
31. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science. 2004 ; 306 (5703). 1954-1957
32. Breimer LH, Mikhailidis DP. Is bilirubin a marker of vascular disease and/or cancer and is it a potential therapeutic target?. Curr Pharm Des. 2011 ; 17 (33). 3644-3655